{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T19:10:22Z","timestamp":1731611422618,"version":"3.28.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"DOI":"10.7759\/cureus.56559","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T16:06:16Z","timestamp":1710950776000},"source":"Crossref","is-referenced-by-count":0,"title":["Bevacizumab-Induced Cutaneous Lupus Erythematosus in a Patient With Metastatic Colon Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Sethi","family":"Ashish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000231481.07654.fc","article-title":"Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response","volume":"17","author":"Gotlib V","year":"2006","unstructured":"Gotlib V, Khaled S, Lapko I, Mar N, Saif MW. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs. 2006, 17:1227-9. 10.1097\/01.cad.0000231481.07654.fc","journal-title":"Anticancer Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10110.x","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus","volume":"164","author":"Lowe GC","year":"2011","unstructured":"Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011, 164:465-72. 10.1111\/j.1365-2133.2010.10110.x","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.02.006","article-title":"Cutaneous drug-induced lupus erythematosus: clinical and immunological characteristics and update on new associated drugs","volume":"148","author":"Bataille P","year":"2021","unstructured":"Bataille P, Chasset F, Monfort JB, et al.. Cutaneous drug-induced lupus erythematosus: clinical and immunological characteristics and update on new associated drugs. Ann Dermatol Venereol. 2021, 148:211-20. 10.1016\/j.annder.2021.02.006","journal-title":"Ann Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.5070\/D32511046136","article-title":"Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature","volume":"25","author":"Shakhbazova A","year":"2019","unstructured":"Shakhbazova A, Marsch AF. Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature. Dermatol Online J. 2019, 25:13030.","journal-title":"Dermatol Online J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1334718","article-title":"Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature","volume":"11","author":"Khorasanchi A","year":"2024","unstructured":"Khorasanchi A, Korman AM, Manne A, Meara A. Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. Front Med (Lausanne). 2024, 11:1334718. 10.3389\/fmed.2024.1334718","journal-title":"Front Med (Lausanne)"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.5070\/D3233034281","article-title":"An update in drug-induced subacute cutaneous lupus erythematosus","volume":"23","author":"Michaelis TC","year":"2017","unstructured":"Michaelis TC, Sontheimer RD, Lowe GC. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J. 2017, 23:13030.","journal-title":"Dermatol Online J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2013.0517","article-title":"Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair","volume":"3","author":"Johnson KE","year":"2014","unstructured":"Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle). 2014, 3:647-61. 10.1089\/wound.2013.0517","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nature03987","article-title":"Pathophysiological consequences of VEGF-induced vascular permeability","volume":"437","author":"Weis SM","year":"2005","unstructured":"Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005, 437:497-504. 10.1038\/nature03987","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.009","article-title":"Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study","volume":"81","author":"Guicciardi F","year":"2019","unstructured":"Guicciardi F, Atzori L, Marzano AV, et al.. Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. J Am Acad Dermatol. 2019, 81:403-11. 10.1016\/j.jaad.2019.02.009","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-785","article-title":"Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report","volume":"7","author":"Wong NY","year":"2014","unstructured":"Wong NY, Parsons LM, Trotter MJ, Tsang RY. Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report. BMC Res Notes. 2014, 7:785. 10.1186\/1756-0500-7-785","journal-title":"BMC Res Notes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-022-00576-5","article-title":"Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer","volume":"12","author":"Tokunaga M","year":"2023","unstructured":"Tokunaga M, Nawata S, Komoto T, Mathuura R, Ichikura D, Watanabe T, Sasaki T. Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer. Int Cancer Conf J. 2023, 12:49-52. 10.1007\/s13691-022-00576-5","journal-title":"Int Cancer Conf J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86482-x","article-title":"Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"11","author":"Bang YH","year":"2021","unstructured":"Bang YH, Kim JE, Lee JS, Kim SY, Kim KP, Kim TW, Hong YS. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Sci Rep. 2021, 11:7118. 10.1038\/s41598-021-86482-x","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169860-bevacizumab-induced-cutaneous-lupus-erythematosus-in-a-patient-with-metastatic-colon-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T18:35:38Z","timestamp":1731609338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169860-bevacizumab-induced-cutaneous-lupus-erythematosus-in-a-patient-with-metastatic-colon-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.56559","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}